Newsroom
In The Headlines
Simberkoff MS, Arbeit RD, Johnson GR, et al.
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010 May 4;152(9):545-554.
View AbstractSafety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010 May 4;152(9):545-554.
Hurley LP, Lindley MC, Harpaz R, et al.
Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010 May 4;152(9):555-560.
View AbstractBarriers to the use of herpes zoster vaccine. Ann Intern Med. 2010 May 4;152(9):555-560.
Angel K, Provan SA,Gulseth HL, et al.
Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010 Feb;55(2):333-338.
View AbstractTumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010 Feb;55(2):333-338.
Griffiths CE, Strober BE, van de Kerhof P, et al.
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14;362(2):118-28.
View AbstractComparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010 Jan 14;362(2):118-28.
June 2010
Tollefson MM, Crowson CS, McEvoy MT, Maradit Kremers H.
Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010 Jun;62(6):979-987.
View AbstractIncidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010 Jun;62(6):979-987.
March 2010
Pavelka K, Jarosova K, Suchy D, et al.
Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-1289 doi:10. 1136/ard.2008.090860.
View AbstractIncreasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009;68:1285-1289 doi:10. 1136/ard.2008.090860.
Mariette X, Tubach F, Bagheri H, et al.
Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400-408 doi:10.1136/ard.2009.117762.
View AbstractLymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010;69:400-408 doi:10.1136/ard.2009.117762.
Strangfeld A, Listing J, Herzer P, et al.
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb 18;301(7):737-744.
View AbstractRisk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb 18;301(7):737-744.
Burmester GR, Mease P, Dijkmans BA, et al.
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009 Dec;68(12):1863-1869. Epub 2009 Jan 15.
View AbstractAdalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis. 2009 Dec;68(12):1863-1869. Epub 2009 Jan 15.
Kay J, Westhovens R
Methotrexate: the gold standard without standardisation. Ann Rheum Dis 2009;68:1081-1082 doi: 10. 1136/ard.2008. 102822.
View AbstractMethotrexate: the gold standard without standardisation. Ann Rheum Dis 2009;68:1081-1082 doi: 10. 1136/ard.2008. 102822.





